Aelis Farma: Publication of the 2021 Annual Financial Report

Aelis Farma: Publication of the 2021 Annual Financial Report
CANNANNEW REPORT

BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 – ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the « Company »), announces today that its annual financial report for the financial year ended December 31, 2021 has been made available to the public and filled with the French Financial Markets Authority (Autorité des marchés financiers). The Company’s annual financial report includes: – the management report; – the report on corporate governance; – the annual financial statements; – the statutory auditors’ reports. It can be consulted on the Company’s website at http://www.aelisfarma.com. *** About AELIS FARMA Founded in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). These new molecules hold great potential in the treatment of many brain diseases. CB1-SSi were developed by Aelis Farma on the basis of the discovery of a new natural defense mechanism of the brain made by the team of Dr. Pier Vincenzo Piazza, CEO of the Company, when he was Director of the Inserm Magendie Neurocentre in Bordeaux. For these discoveries, Dr. Piazza was awarded the Grand Prix of Inserm, and the Grand Prix of Neurology of the French Academy of Sciences, which are among the most prestigious French awards for medicine and neurology. Aelis Farma is developing two first-in-class drug candidates that are at the clinical stage, AEF0117 and AEF0217, and has a portfolio of innovative CB1-SSi for the treatment of other diseases associated with dysregulation of CB1 receptor activity. AEF0117, which targets the disorders due to excessive cannabis use (addiction and psychosis), has demonstrated efficacy in a phase 2a clinical trial and will enter a phase 2b clinical trial in the United States…

Excerpt only …
READ MORE BELOW
Source : Aelis Farma: Publication of the 2021 Annual Financial Report

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.